Celgene walks away from Oncomed’s navicixizumab

21st September 2018 Uncategorised 0

Celgene has decided not to exercise its option to license OncoMed’s bispecific antibody navicixizumab.

More: Celgene walks away from Oncomed’s navicixizumab
Source: News